Kornimate/medical-research-clean huggingface dataset:
cardio protective properties of a yogurt enriched with bioactive lipids of olive oil products

Conditions: Cardiovascular Diseases

Summary: this study evaluates the effectiveness of a yogurt enriched with bioactive lipids extracted from olive mill waste in platelet aggregation and other inflammatory and oxidative stress markers. the study will include three groups: the intervention group will receive the enriched yogurt while the other two groups will serve as controls (plain yogurt and no yogurt consumption).

cardiovascular diseases are the leading cause of mortality worldwide. data from the investigators research group indicate that platelet activating factor (paf) is one of the most important inflammatory factors and the main mediator of thrombosis during the formation of atherosclerotic plaque. thus, dietary interventions aimed at inhibition of paf is of particular importance in public health level. the aim of the study is to examine the efficacy of administering in humans bioactive lipids extracted from olive mill waste (with proven in vitro anti-thrombotic activity and in vivo anti-atherosclerotic properties in rabbits fed an atherogenic diet) to inhibit the activity of paf and other inflammatory mediators. bioactive lipids are isolated by standardized methodology of oil manufacture byproducts. preliminary studies have been done in animals to establish the safety of administration of these compounds and to clarify the effective dosages of administration for inhibiting formation of atherosclerotic plaques. the effectiveness of these compounds in humans will be examined in a randomized, double-blind clinical trial in subjects aged 40-60 years, lasting eight weeks. supplementation with the bioactive lipids will be in the form of an enriched yogurt provided daily. the study includes three groups: treatment group, where enriched yogurt will be provided, plain yogurt treatment group and no consumption of yogurt group . parameters that will be assessed are the inhibition of platelet aggregation (with three different stimuli, including paf), lipid profile, inflammatory markers such as crp, il-6, tnfa, and oxidative stress markers.

Eligibility criteria:
inclusion criteria: * all individuals, aged 40-60 years, without any of the exclusion criteria exclusion criteria: * any anti-inflammatory medication * hyper-lipidemic medications * use of antibiotics within two months from study entry * pregnancy or childbirth in the previous year * intake of any nutritional supplement * any serious dental, respiratory, liver, kidney, gastrointestinal disease

Keywords: platelet activating factor inflammatory markers yogurt olive oil platelet aggregation oxidative stress endothelial damage bioactive lipids
transcranial direct current stimulation (tdcs) in the treatment of anorexia nervosa

Conditions: Anorexia Nervosa

Summary: anorexia nervosa (an) is a serious and often chronical eating disorder characterized by an extreme effort for weight loss and intense fear of becoming fat despite the obvious thinness. the treatment is very difficult and not always effective. that´s the reason why we are looking for new ways of the therapeutic approach. transcranial direct current stimulation (tdcs) is a neuromodulation technique, which modulates the neuronal excitability. according to previous research it has a potential to help people with anorexia nervosa. the device for the tdcs has two electrodes, an anode (the excitatory one) and a cathode (the inhibitory one). we put them on the skull into the different positions, in dependence on the fact, if we want to excite or on to inhibit the parts of the brain under the electrodes. there are several hypothesis how could the tdcs help in patients with an. one of them speaks about the hyperactivity of the right hemisphere in anorexia nervosa. therefore could the anodal (excitatory) tdcs over the left hemisphere and the cathodal (inhibitory one) help in resetting the inter-hemispheric balance.

stimulation of 2 milliampere is applied for 30 minutes in every real session. together there are 10 sessions, the application is every workday within 2 weeks. all measurements and questionnaires are made 4 times: 1. before the stimulation 2. on the day of the last stimulation 3. 14 days after the last stimulation 4. 28 days after the last stimulation

Eligibility criteria:
inclusion criteria: * patients with the diagnosis of anorexia nervosa exclusion criteria: * patients: with the diagnosis of epilepsy, after a serious injury of head, with chronic headache, with some metal or electronic implants in their heads and patients who are pregnant.

Keywords: transcranial direct current stimulation (tdcs)
bis monitoring of patients with hydrocephalus

Conditions: Hydrocephalus

Summary: we tested the hypothesis that bis values are altered in pediatric patients with hydrocephaly. we also tested the hypothesis that bis values are altered in adult post cerebral hemorrhage patients with hydrocephaly undergoing ventricular-peritoneal shunt placement

context: enlarged skull circumference in patients with hydrocephalus might alter bispectral index (bis) values; as distorted skull contour distances sensors from a shifted cerebral mass as well as mental dysfunction as a result of disrupted cerebrospinal fluid circulation. objectives: investigators tested the hypothesis that bis values are altered in pediatric patients with hydrocephaly. investigators also tested the hypothesis that bis values are altered in adult post cerebral hemorrhage patients with hydrocephaly undergoing ventricular-peritoneal shunt placement. methods: after ethics committee approval participants, or their next of kin, who gave written informed consent were recruited in the study. investigators excluded potential participants suffering from hepatic disease. in the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group were included in the study. in the second study 15 post cerebral hemorrhage adult patients undergoing ventricular-peritoneal shunt placements and 15 adult control patients were included in the study. 2 bis sensors were placed on patients' forehead and connected to bis-vista monitors. in a quiet anesthesia induction room investigators recorded bis-vista for 10 min before induction. remifentanil 4 ng ml-1 was started and propofol tci was kept constant at 4 microg ml-1 with no adjustments for a 1 h anesthesia maintenance study-recording period when time of surgery allowed. investigators also noted bis values immediately before and after a patent ventricular-peritoneal shunt was successfully installed. after conclusion of surgical procedures, remifentanil and propofol infusions were terminated and this marked the beginning of the recovery phase of the study where we recorded bis values for another 20 min emergence from anesthesia.

Eligibility criteria:
inclusion criteria: . in the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study. in the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study. exclusion criteria: patients with liver disease

Keywords: bispectral index hydrocephalus
real life study on iron isomaltoside 1000 in the treatment of id in ckd, heart failure, obgyn, ibd, cancer and elective surgery (real-choice).

Conditions: Iron-Deficiency Anemia; Iron-Deficiency

Summary: real-choice - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards iv (intravenous) iron therapy in general and iim (iron isomaltoside 1000) treatment particularly before and after iim treatment in iron deficient patients with or without anemia in the real-world clinical setting after commercial availability of this product in switzerland.


Eligibility criteria:
inclusion criteria: * legally capable male and female patients, aged ≥ 18 years (no upper limit); * written informed consent of the patient with regard to the pseudonymized documentation; * the patients are not selected by specific inclusion or exclusion criteria, but by the indication listed in the swiss smpc (summary of product characteristics) of monofer®; * decision is taken to treat the patient with iim in accordance with the current swiss smpc of monofer® and by prescription; this decision is taken prior to and independent from the inclusion into the study. exclusion criteria: * any contraindication regarding iim treatment as specified in the swiss smpc of monofer®; * retrospective observation of iim infusion; * current or upcoming participation in an interventional clinical trial; * prior iv iron treatment or transfusion within 3 months prior to enrolment; * instable and/or untreated comorbidities potentially hampering the observation of the primary outcome parameter of this study; * prisoners or persons who are compulsorily detained (involuntarily incarcerated).

Keywords: iron isomaltoside 1000 iron derisomaltose 1000
clinical efficacy of preformed pediatric zirconia and metal crown

Conditions: Carious Teeth

Summary: the study was planned to evaluate and compare the clinical success of prefabricated stainless steel crowns and zirconia crowns used in the primary molars. the study will be carried out in healthy children aged 6-9 years with caries on more than one surface of the primary molars.

in this study, zirconia crowns will be compared with prefabricated stainless steel crowns in a randomized controlled manner. the study will be conducted in split-mouth to eliminate the effect of potential confounders. the obtained data will be analyzed using appropriate statistical methods.

Eligibility criteria:
inclusion criteria: * healthy children aged 6-9 years with caries on primary molars * children without systemic disease or developmental dental anomalies that may affect caries susceptibility. * children whose cooperation is 'positive' or 'absolutely positive' according to the frankl behavioral scale (frankl et al., 1962). * those with deep dentin caries that do not extend to the pulp in the teeth to be treated * the molars will be treated with a crown indication. * presence of symmetry of the primary molar to be treated in the opposite arch. * the molar to be treated is in occlusion with the antagonist. * presence of caries on at least two surfaces of the molars to be treated. * absence of spontaneous pain, abscess, mobility, interradicular lesion in the tooth to be treated * patients whose parents and themselves agree to participate in the treatment exclusion criteria: * children whose treatment cannot be continued on the dental chair due to cooperation * molars that will soon be exfoliated, 1/2 of the root has been resorbed * the presence of bruxism * the presence of erosion or attrition-related wear on the opposing molar * the patient does not come to the control appointment or does not want to continue to the research * have allergy to local anesthetic, nickel or chromium * complications during treatment.
singapore cardiac longitudinal outcomes database

Conditions: Coronary Artery Disease; Congestive Heart Failure; Atrial Fibrillation

Summary: the research project aims to perform data extraction, integration and analysis across multiple clinical, administrative, financial and pharmacy databases in the participating institutions. the key data components will include clinical cardiovascular specific data, procedural data, financial and administrative data (e.g. cost of medications and supplies, length of stay, diagnosis codes etc.), short-to-long term clinical outcomes (including hospital re-admissions, cardiovascular events, death), and quality-of-care indices (e.g. compliance to guideline-recommended therapy and medications). the research project will involve all patients proven and/or suspected with coronary artery disease (cad), congestive heart failure (chf) and atrial fibrillation (af) admitted to national heart centre singapore (nhcs) and nuh.

the research project is initiated by nhcs and its participating institutions include ministry of health (moh), as well as national university hospital (singapore) pte ltd (nuh), changi general hospital (cgh), khoo teck puat hospital (ktph), singapore general hospital (sgh), tan tock seng hospital (ttsh), ng teng fong general hospital (ntfgh) , singhealth polyclinics, national healthcare group polyclinics (nhgp), sengkang hospital (skh), national university polyclinics (nup), and alexandra hospital (ah). the research project will leverage on the health data grid (hdg) pilot project, now known as business research analytics insights network (brain). brain will be a virtual repository that will enable access to anonymised and merged data from disparate databases at multiple institutions. the structures of brain will preserve patients' privacy and confidentiality, ensure it security and allow access only by authorised persons. the brain pilot project will be co-funded by moh and the infocommunication media development authority of singapore (imda). to avoid doubt, after the brain pilot project, a separate approval from the appropriate stakeholders will have to be sought for further funding of the operating costs of the brain, regardless of whether the value of the brain has been demonstrated during the brain pilot project. there is no direct cost involved in the research project. for the research project, moh will contribute administrative data from the registry of births and deaths, casemix \& subvention, the mediclaim, and omnibus databases, and the other participating institutions will contribute the data from the national electronic health records (nehr), electronic health intelligence system (ehints) and enterprise data warehouse (edw) to brain. only anonymised data from brain will be utilised for the research project.

Eligibility criteria:
inclusion criteria: * all patients who present to a healthcare institution with either cad or suspected cad (including chest pain); chf or suspected chf; af or suspected af exclusion criteria: * non-singaporeans

Keywords: cad chf af singcloud cardiovascular retrospective brain hdg database
comparison of cervical pathologies in the presence of high risk hpv positivity

Conditions: Human Papilloma Virus; Cervical Neoplasm

Summary: the only malignancy screening test among gynecological cancers is cervical cancer. cytology examination and hpv typing with smear are used as screening tests. hpv positivity is detected in more than 90% of cervical cancers. however, only the hpv 16-18 type positive patients undergo colposcopy in the routine screening program. patients with smear negative, type 16-18 high-risk hpv positivity are evaluated by quota after 1 year. the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 hpv positivity and type 16-18 high-risk hpv positivity and to find out whether there was any difference between them. in this way, other high-risk hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.


Eligibility criteria:
inclusion criteria: * 20-65 years old * patients with normal smear exclusion criteria: * patients with invasive cervical cancer, * hiv-positive patients, * ascus and more risky premalignant lesions in cytology, * over the age of 65 and * patients under 20 years of age, * patients with another known gynecological malignancy

Keywords: colposcopy high risk hpv
pegylated liposomal doxorubicin as a induction therapy for lymphoma induced hemophagocytic lymphohistiocytosis.

Conditions: Hemophagocytic Lymphohistiocytosis

Summary: this study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin together with etoposide and methylprednisolone as a induction therapy for lymphoma induced hemophagocytic lymphohistiocytosis.


Eligibility criteria:
inclusion criteria: * 1.diagnosed as lymphoma-hemophagocytic lymphohistiocytosis. * 2.patients were older than 2 years of age. * 3.estimated survival time ≥ 1 week. * 4.cardiac ultrasound lvef≥50%; no active bleeding of the internal organs(digestive tract, lung, brain, etc.); if the patient has dyspnea, oxygenation index \>250. * 5.sign informed consent. exclusion criteria: * 1.heart function above grade ii (nyha). * 2.accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease. * 3.pregnancy or lactating women. * 4.allergic to pegylated liposomal doxorubicin or etoposide. * 5.active bleeding of the internal organs. * 6.hiv antibody positivity. * 7.acute or chronic active hepatitis b (hbsag positivity, hbv dna negative acceptable), acute or chronic active hepatitis c (hcv antibody negatively acceptable; hcv antibody positivity, hcv rna negative acceptable). * 8.participate in other clinical research at the same time. * 9.the researchers considered that patients are not suitable for the study.

Keywords: pegylated liposomal doxorubicin
attention modulation for treatment of parkinson's disease and dementia with lewy bodies

Conditions: Parkinsons Disease; Lewy Bodies Disease

Summary: the purpose of this study is to evaluate if a drug commonly used to treat excessive day-time sleepiness, called armodafinil (nuvigil), is also effective in improving the impairment in the attention commonly reported by patients with more advanced parkinson's disease (pd) and lewy body disease (lbd).

the main aims of this study are: 1. to investigate whether in pdd and dlb th specific disturbances in the basal ganglia thalamocortical network, measured through the electroencephalography (eeg) frequency analysis, are ameliorated by armodafinil. our main hypothesis is that armodafinil can restore the attention and improve cognitive disturbances in pdd and dlb, through a specific effect on striatal-thalamo-cortical activity.

Eligibility criteria:
inclusion criteria: * established criteria for diagnosis of pdd (parkinsons disease) {emre m et al. mov disord 2007;22:1689-707} and dlb (lewy bodies disease) {mckeith et al. neurology 2005;65:1863-72} * mini mental state examination (mmse) score between \<24; and/or dementia rating * scale-2 (drs-2) score \<134; * clinical assessment of fluctuation (caf)\>4; * stable anti-parkinsonian medication in the 4 weeks preceding the study exclusion criteria: * use of cognitive enhancers (donepezil, rivastigmine, galantamine, modafinil, memantine) in the last 4 weeks: concomitant use of any medication contraindicated with modafinil/armodafinil; history of alcohol and substances abuse. use of medications known to alter the normal eeg activity in humans during the study period (i.e. clonazepam) history of psychiatric disorders, other than depression and psychiatric complication of pdd and dlb
real-world data collection of the gore® viabahn® vbx balloon expandable endoprosthesis when used in covered endovascular reconstruction of the aortic bifurcation (cerab) to treat aortoiliac occlusive disease

Conditions: Aortoiliac Occlusive Disease

Summary: the study will assess the safety and effectiveness of the gore® viabahn® vbx balloon expandable endoprosthesis ("vbx device" or also referred to as "vbx stent graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (cerab) to treat aortoiliac occlusive disease (aiod).

a minimum of 158 adult subjects will be enrolled at up to a minimum of 20 sites in the u.s. and europe. data will be collected retrospectively and found within existing site files at baseline, treatment, discharge, pre-12-month follow-up, 12-month follow-up, subsequent follow-up visits.

Eligibility criteria:
inclusion criteria: 1. patient treated with covered endovascular reconstruction of the aortic bifurcation (cerab) procedure for aortoiliac occlusive disease (aiod). 2. patient was implanted with the vbx device in the aortic position during a cerab procedure. 3. patient was treated with the cerab procedure a minimum of 1 year before enrollment date. 4. age ≥18 years at the time of cerab procedure. 5. obtain patient informed consent or waiver according to local institutional review board (irb)/ethics committee (ec) - exclusion criteria: 1. patient with prior stenting in the aortic or common iliac artery at the time of cerab procedure. 2. patient treated with concomitant chimney procedure at time of cerab procedure (e.g., inferior mesenteric artery, renal artery). 3. participation in another drug or device investigational study at the time of the cerab procedure date that can confound the study endpoints. -
a cross-sectional study on the prevalence and extraesophageal symptoms of gastroesophageal reflux disease(gerd) in patients with upper gi symptoms, visiting the outpatient departments of peripheral hospitals in greece

Conditions: Gastroesophageal Reflux Disease

Summary: the present study has been designed to provide current data on gerd prevalence in several regional areas of greece outside the two major urban centres (athens and thessaloniki), to measure the treatment response in gerd patients, and to assess the correlations between the two methods of diagnosing gerd, i.e. reporting of symptoms by the patient to the physician and completion of the gerdq questionnaire by the patient. additionally, this study aims to provide data on the prevalence of extraesophageal symptoms in gerd patients in greece. the xqs questionnaire will be applied for the identification of these patients and the assessment of the extraesophageal disease burden (frequency and intensity/severity). finally, an association between the gerdq and xqs scores will be attempted.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * patients aged 18 and over * patients with upper-gi symptoms during the last week prior to the study visit exclusion criteria: * history of oesophageal, gastric or duodenal surgery * patients with history of malignancy * treatment with acetylsalicylic acid/nsaid during the last week prior to the study visit * therapy with ppi for the healing of ulcer induced by treatment with acetylsalicylic acid/nsaid * therapy with ppi for hp eradication or for healing of hp-related peptic ulcer

Keywords: gastroesophageal reflux disease, extraesophageal symptoms